EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Illumina's enterprise value is $34,994 Mil.
Illumina's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 was $1,196 Mil. Therefore, Illumina's EV-to-EBITDA for today is 29.26.
The historical rank and industry rank for Illumina's EV-to-EBITDA or its related term are showing as below:
ILMN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.57 Med: 36.82 Max: 83.32
Current: 30.54
During the past 13 years, the highest EV-to-EBITDA of Illumina was 83.32. The lowest was 12.57. And the median was 36.82.
ILMN's EV-to-EBITDA is ranked worse than 83.94% of 137
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.37
vs ILMN: 30.54
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-08-10), Illumina's stock price is $225.955.
Illumina's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $4.600. Therefore, Illumina's PE Ratio for today is 49.12.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Illumina EV-to-EBITDA Historical Data
The historical data trend for Illumina's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Illumina Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
EV-to-EBITDA
25.33
37.75
34.78
48.03
50.94
Illumina Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
EV-to-EBITDA
49.56
59.09
47.34
50.94
46.89
Competitive Comparison
For the Diagnostics & Research subindustry, Illumina's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina EV-to-EBITDA Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Illumina's EV-to-EBITDA falls into.
Illumina EV-to-EBITDA Calculation
Illumina's EV-to-EBITDA for today is calculated as:
Illumina's current Enterprise Value is $34,994 Mil.
Illumina's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,196 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (NAS:ILMN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Illumina's share price for today is $225.955.
Illumina's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Illumina's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
11.16(5.19%) Volume: 659,333 3:25PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ILMN has been successfully added to your 
